Vanda Pharmaceuticals | VNDA - Selling And Administration Expenses


Vanda Pharmaceuticals reported $39.28M in Selling and Administration Expenses for its fiscal quarter ending in December of 2024.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 146.73M 21.82M Dec/2025
Agios Pharmaceuticals USD 38.46M 4.51M Mar/2026
Akebia Therapeutics USD 23.53M 3.19M Dec/2025
Alnylam Pharmaceuticals USD 282.51M 2.55M Mar/2026
Anika Therapeutics USD 10.01M 14K Dec/2025
Arrowhead Research USD 46.02M 8.84M Dec/2025
AstraZeneca USD 5.06B 455M Mar/2026
Bristol-Myers Squibb USD 1.62B 564M Mar/2026
Eli Lilly USD 2.93B 198M Mar/2026
Enanta Pharmaceuticals USD -1.05 0.31 Dec/2024
Esperion Therapeutics USD 39.42M 456K Dec/2025
Halozyme Therapeutics USD 64.64M 27.11M Dec/2025
Heron Therapeutics USD 23.74M 605K Dec/2025
Insmed USD 212.48M 26.11M Dec/2025
J&J USD 6.03B 719M Mar/2026
Lexicon Pharmaceuticals USD 3.98M 195K Dec/2025
Ligand Pharmaceuticals USD 28.45M 8.27M Sep/2025
Merck USD 2.67B 180M Mar/2026
Minerva Neurosciences USD 2.48M 58.79K Sep/2024
Moderna USD 173M 135M Mar/2026
Novartis USD 3.44B 132M Dec/2025
Pfizer USD 4.08B 894M Dec/2025
PTC Therapeutics USD 87.2M 3.15M Dec/2025
Puma Biotechnology USD 16.82M 8.15M Sep/2024
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Sanofi EUR 2.33B 419M Mar/2026
Takeda JPY 282.78B 29.23B Dec/2025
Teva Pharmaceutical Industries USD 1000M 120M Mar/2026
Ultragenyx Pharmaceutical USD 89M 2.38M Dec/2025
Vanda Pharmaceuticals USD 39.28M 1.71M Dec/2024
Veracyte USD 43.31M 8.43M Dec/2025